- Home
- RERE vs INBX Comparison
RERE vs INBX Comparison
Compare RERE & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | INBX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.6M | 999.7M |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RERE | INBX |
|---|---|---|
| Price | $4.75 | $133.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | ★ 627.9K | 486.3K |
| Earning Date | 05-19-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $25.70 | N/A |
| Revenue Next Year | $22.93 | N/A |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $2.41 | $12.80 |
| 52 Week High | $6.47 | $155.29 |
Technical Indicators
Market Signals| Indicator | RERE | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 66.58 |
| Support Level | $4.23 | $69.30 |
| Resistance Level | $4.89 | $155.29 |
| Average True Range (ATR) | 0.18 | 13.75 |
| MACD | 0.02 | 0.62 |
| Stochastic Oscillator | 67.91 | 69.23 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.